There is virtually no evidence for the use of Trazodone to treat ME/CFS. In 2012 Solve ME/CFS Initiative contracted Biovista to use drug models to identify existing drugs that may be worth investigating for treatment. The results suggested Trazodone was worth considering.
Notable studies[edit | edit source]
- 2008, Nitric oxide modulation mediates the protective effect of trazodone in a mouse model of chronic fatigue syndrome
- 2010, Trazodone for the treatment of fibromyalgia: an open-label, 12-week study
- 2011, Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study
Media coverage[edit | edit source]
See also[edit | edit source]
Learn more[edit | edit source]
References[edit | edit source]
- "Trazodone: MedlinePlus Drug Information". medlineplus.gov. Retrieved Jan 9, 2019.
- Solve ME/CFS Initiative - Results of Biovista Work Released
- Kumar, Anil; Garg, Ruchika; Kumar, Puneet (October 2008), "Nitric oxide modulation mediates the protective effect of trazodone in a mouse model of chronic fatigue syndrome", Pharmacological reports: PR, 60 (5): 664–672, ISSN 1734-1140, PMID 19066412
- Morillas-Arques, Piedad; Rodriguez-Lopez, Carmen Ma; Molina-Barea, Rocio; Rico-Villademoros, Fernando; Calandre, Elena P. (Sep 10, 2010), "Trazodone for the treatment of fibromyalgia: an open-label, 12-week study", BMC musculoskeletal disorders, 11: 204, doi:10.1186/1471-2474-11-204, ISSN 1471-2474, PMC , PMID 20831796
- Calandre, Elena P.; Morillas-Arques, Piedad; Molina-Barea, Rocío; Rodriguez-Lopez, Carmen M.; Rico-Villademoros, Fernando (May 16, 2011), "Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study", BMC musculoskeletal disorders, 12: 95, doi:10.1186/1471-2474-12-95, ISSN 1471-2474, PMC , PMID 21575194
mouse model - The use of special strains of mice to study a human disease or condition, and how to prevent and treat it
chronic fatigue syndrome (CFS) - A controversial term, invented by the U.S. Centers for Disease Control, that generally refers to a collection of symptoms as “fatigue”. There have been multiple attempts to come up with a set of diagnostic criteria to define this term, but few of those diagnostic criteria are currently in use. Previous attempts to define this term include the Fukuda criteria and the Oxford criteria. Some view the term as a useful diagnostic category for people with long-term fatigue of unexplained origin. Others view the term as a derogatory term borne out of animus towards patients. Some view the term as a synonym of myalgic encephalomyelitis, while others view myalgic encephalomyelitis as a distinct disease.